VPIM
RUBY

Vanguard Personalized Indexing Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,753
Closed -$5K – 1364
2022
Q3 		$5K Buy
+10,753
New +$8.06K ﹤0.01% 1229

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Personalized Indexing Management's RUBY Position: Q4 2022 in Review

Vanguard Personalized Indexing Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 10,753 shares — an estimated $5K sold.

Vanguard Personalized Indexing Management first reported a position in RUBY in Q3 2022 and held it in 1 quarter. The position peaked at $5K in Q3 2022. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Vanguard Personalized Indexing Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 10,753 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $5K.
  • Vanguard Personalized Indexing Management first reported a position in Rubius Therapeutics, Inc in Q3 2022 and held it in 1 quarter.
  • Vanguard Personalized Indexing Management's Rubius Therapeutics, Inc position peaked at $5K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Vanguard Personalized Indexing Management's 13F filing for Q4 2022, filed 10 Feb 2023.